Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
4Customers
3Debt Items
4Related Chains
Source-Backed Evidence Depth
Tarsus Pharmaceuticals, Inc. (TARS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
6High confidence
0.812Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from ELAN graph: Reciprocal relationship from TARS graph: Reciprocal relationship from ELAN graph: Reciprocal relationship from TARS graph: Reciprocal relationship from ELAN g…
Tarsus Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
LIMITED-SPECIALTY-PHARMACIES
LIMITED-SPECIALTY-PHARMACIES
90%
The Company periodically enters into agreements with certain limited specialty pharmacies and specialty distributors for the sale of XDEMVY in the U.S.
XI-AN-GRAND-CHANG-AN-PHARMACEUTICAL-CO-LTD
XI-AN-GRAND-CHANG-AN-PHARMACEUTICAL-CO-LTD
85%
in China for the treatment of Demodex blepharitis and Meibomian Gland Disease (“MGD”) to Xi An Grand Chang An Pharmaceutical Co., Ltd. (“GrandPharma”). Revenue is recognized in proportion to the allo…
Reciprocal relationship from ELAN graph: Reciprocal relationship from TARS graph: ation of our product or our product candidates, including XDEMVY for the treatment of Demodex blepharitis, TP-04 for …
ELANCO-TIERGESUNDHEIT-AG
ELANCO-TIERGESUNDHEIT-AG
62%
ation of our product or our product candidates, including XDEMVY for the treatment of Demodex blepharitis, TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease pro…
Tarsus Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TARS-DEBT-12882
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
TARS-DEBT
Debt stack $72.8M
90%
Market cache reports total debt of $72.8M.
TARS-DEBT-12881
Warrants outstanding: 312500
90%
xbrl warrant detail from xbrl 2026-03-31.
Tarsus Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tarsus Pharmaceuticals, Inc..
Tarsus Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
TARS-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 256 tracked holders.
Tarsus Pharmaceuticals, Inc. Extended Supply Chain Network
